In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com

OBP Sessions:

April 29th, 3:00 PM - 4:00 PM ET

Register Now

May 3rd, 10:30 AM - 11:30 AM ET

Register Now

May 22nd, 3:00 PM - 4:00 PM ET

Register Now

This CME program is supported by an educational grant from Gilead Sciences, Inc.

This educational activity is directed toward medical oncologists, NP/PAs, pharmacists, and nurses.

Upon completion of this activity, participants will be able to:

• Discuss unmet clinical needs in the management of patients with HR+ breast cancer in the context of recent evidence on TROP2-directed therapies that have been evaluated
• Explain the safety profile and methods to manage treatment-related toxicities among patients who receive TROP2-directed antibody drug conjugates in HR+/HER2- breast cancer settings
• Identify strategies to address barriers associated with community practice management of patients with metastatic HR+/HER2- MBC
• Determine how recent data from trials evaluating approaches for HR+/HER2- breast cancer care can be considered in the context of the patient perspective, as well as racial, ethnic, and socioeconomic backgrounds

• Review the clinical data on approved and emerging TROP2-targeted therapies for treatment of HR+/HER2- metastatic breast cancer (MBC)
• Learn how the experts and your peers are managing challenging cases for their patients with progressing HR+/HER2- MBC
• Ask the experts about best practices for increasing access to optimal therapy for patients with HR+/HER2- MBC

Komal Jhaveri, MD, FACP

Physicians’ Education Resource (PER) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity will be made available for 1.0 AMA PRA Category 1.0 Credits.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hours.